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The Lung Mast Cell: Its Physiology
and Potential Relevance to Defense
of the Lung
by Stephen 1. Wasserman*
The mast cell, located at mucosal surfaces and surrounding venules, is uniquely positioned to respond
rapidly to insults to the host by mediating the development of a wide-ranging inflammatory response.
Activation of the mast cell releases preformed granule-associated chemical mediators and generates
de novo biologically active materials. Thepropertiesofthemastcellmediatorspermitdevelopmentofboth
acute and prolonged inflammatory responses. The immediate response ischaracterized by edema and the
delayed response by leukocyte infiltration and vascular damage.
The mast cell mediators responsible for these inflammatory events are characterized functionally. The
vasoactive/smooth muscle reactive mediators include preformed histamine and serotonin and newly-
generated platelet activating factor, slow reacting substance ofanaphylaxis and prostaglandins. Chemo-
tacticmediators includeeosinophil-selective ECF-AandECF-oligopeptides, neutrophil-selective NCF, and
lipidchemotacticmediatorswithbroadspecifcity. Thesefactorsinducedirectedmigrationandlocalization
of leukocytes. The mast cell releases the structural proteoglycan, heparin, which is anticoagulant and
inhibitscomplement. Released mastcell enzymesincludechymotryptic andtrypticproteases,arylsulfatase,
,8-glucuronidase, andhexosaminidase. Theproteolytic enzymesmayactivateinflammatory pathwayswhile
the others degrade ground substance. The capacity of the mast cell to enhance vascular permeability, to
cause the influx of regulatory or inflammatory leukocytes, and to provide a variety of active enzymes
permits regulation of inflammatory events at the site of tissue injury.
The mast cell, with its specific immunologic re-
ceptors, is positioned at portals of entry of poten-
tially toxic or noxious exogenous material. In the
lung the mast cell is located free in the bronchial
lumen, in the bronchial mucosa in intra-epithelial
locations, as well as in deeper perivenular collec-
tions (1, 2). As it is present prior to entry ofnoxious
agents and is thus freed from the requirements of
mobilization and localization, the mast cell may be
the sentinel cell for induction of local inflammatory
responses. The development of inflammation by
mast cells is consequent to the release of its content
ofpotentbiologic mediators as well asbyitscapacity
to generate, de novo, active biologic materials from
the local microenvironment. The knowledge that
mediators are active in vivo follows from thein vitro
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definition oftheir biologic activities which relate to
the known pathophysiology of inflammation. The
inflammatory process induced by mast cell media-
tors is both acute and chronic and is subject to both
positive and negative feedback controls inherent in
the properties ofthe mediators themselves. It is the
purpose ofthis review to delineate the physiology of
the mastcell, the mediators generated uponmastcell
activation and the regulation ofmast cell-dependent
inflammatory events.
Mast Cells
Mast cells are present in human lung at concentra-
tions of 1-7 x 106f cells/g lung tissue (3). Each mast
cell possesses, in addition to the ubiquitous subcel-
lularorganelles essential for all cellfunction, several
hundred metachromatically staining granules each
surrounded by a bilayer membrane. Lung mast cell
granules possess a definite subgranular architecture
(Fig. 1) of unknown functional significance. The
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FIGURE 1. Electron micrograph of isolated human lung mast cell. Nucleus (N), membrane microvilli (MV), granule (G).
mast cell membrane is ruffled and possesses 50-
300,000 receptors for IgE (4). IgE molecules belong
to an immunoglobulin class defined by its activity in
mediating immediate hypersensitivity reactions and
by characteristic physicochemical properties. It
comprises two heavy and light chains linked by di-
sulfide bridges with a total molecular weight of
190,000. It is heat-labile, but does not form precipi-
tates with specific antigen nor does it fix comple-
ment. The serum concentration of IgE is under
genetic control, being higher inatopic thanin normal
individual(s). Papain digests IgE into three frag-
ments, two ofwhich (Fab) bind specific antigen and
one (Fc) which binds to the specific receptors upon
the mast cell surface. Receptors for the anaphyla-
toxins, C3a and C5a, fragments ofthe third and fifth
components ofcomplement, respectively, have been
attributed tothe mastcell uponfunctional criteria. In
addition, mast cells may be degranulated by non-
immunologic stimuli. Thus enzymes such as
chymotrypsin, phospholipases A and C, and
sialidase, ionophores, polycationic amines and pro-
teins, radio-contrast media, and opiates may all ef-
fect mast cell degranulation. While it is generally
assumed that atopic individuals exhibit their anti-
gen-induced symptoms as a result ofIgE-dependent
mast cell activation, the demonstration of non-IgE
mediated mechanisms for mast cell mediator release
does not diminish the primacy of IgE in allergy but
rather yields additional information on potential
mechanisms for recruitment of mediators.
Activation and Degranulation of
Mast Cells
The IgE-dependent degranulation of mast cells is
initiated by the bridging ofpairs ofcell-bound IgE by
specific antigen and terminates in 2 min. Bridging
results in an alteration of the cell membrane which
probably activates a surface membrane esterase.
The cell membrane perturbation thus initiated is also
associated with increasedenergy-dependentcalcium
entry into the cell. The calcium requirement for de-
granulation is related to the activation of the mem-
brane serine esterase, and perhaps also to require-
ments for the expression of phospholipase activity,
microfilament contraction, or membrane fusion. De-
granulation also requires glucose and an intact
glycolytic pathway. Finally, both ATP and calcium
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FIGURE 2. Schematic representation of proposed metabolic pathways relevant to antigen-induced
degranulation of mast cells.
are required by acalcium-dependent ATPase, which
probably activates contractile proteins. Following
the ordered completion of these processes the peri-
granular membranes fuse with each other and with
the cell membrane, and the granules are extruded
(Fig. 2). Degranulation may be modulated at several
steps in its sequence by endogenous or exogenous
agents. Thus elevations in intracellular levels of
cyclic adenosine 3'5'-monophosphate (cAMP), which
may be induced by prostaglandins, histamine, and
,3-adrenergic agents, inhibit degranulation (6). Con-
versely, a-adrenergic or prostaglandin-induced falls
in cAMP or rises in intracellular cyclic guanosine
3'5'-monophosphate (cGMP) following interaction
with cholinergic stimuli or histamine, may enhance
degranulation (6). The opposing actions ofthe cyclic
nucleotides and the bidirectional control of de-
granulation by cAMP are felt to represent competi-
tive effects upon a putative protein kinase which
might regulate the state of cytoskeletal assembly.
The supposition that cytoskeletal elements are im-
portant in human mast cell degranulation is sup-
ported by the inhibitory effects upon degranulation
of colchicine and by the augmentation induced by
cytochalasin B (7, 8).
Mast Cell-Dependent Mediators
Mast cells possess within their granules a variety
ofvasoactive, bronchospastic, and chemotactic me-
diators as well as a variety of active enzymes and
structural proteoglycans (Table 1). Mast cell activa-
tion leads to the release ofthese preformed granular
elements as well as to the generation ofpotent bron-
chospastic, vasoactive and chemotactic substances.
Although best delineated in the case of the rat mast
cell, it is likely that the human mast cell will befound
similar in these regards.
Bronchospastic and Vasoactive Mediators
Histamine. Histamine, the product ofdecarboxy-
lation ofthe amino acid histidine, is ionically bound
to the proteoglycan-protein backbones of mast cell
granules and is displaced by sodium exchange in the
extracellular fluid (9). Histamine is catabolized by
either oxidative deamination (histaminase) or by
combined methylation and oxidative deamination
(histaminase plus histamine N-methyl transferase
(10). The pulmonary effects of histamine are ex-
pressed as both direct and reflex constriction ofboth
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155Table 1. Mast cell-dependent mediators.
Structural
Mediator characteristics Function Inhibition Inactivation
Bronchospastic and Vasoactive Activity
Histamine
(preformed)
SRS-A
(newly generated)
Serotonin
(preformed)
PAF(s)
(newly generated)
Arachidonic
acid metabolites
PGD, PGE, PGI,
PGF2a, HETE
,f-Imidazolyl-
ethylamine,
MW 111
Acid hydrophilic
sulfur-containing
lipid (?), MW - 400
5-OH-tryptamine,
MW 182
Lipid-like,
MW 400-1000
C20 fatty acids
(HHT C17 fatty acid)
Contraction of smooth muscle
Increase of vascular permeability
Stimulation of suppressor
T-lymphocytes
Generation of prostaglandins
Enhancement of (Hi) or
inhibition (H2) of chemotaxis
Elevation of cAMP (H2)
and cGMP (Hi)
Contraction of smooth muscle
Increased vascular permeability
Synergistic with histamine
Generation of prostaglandins
Contraction of some smooth
muscle
Increased vascular permeability
Release of platelet amines
Platelet aggregation
Sequestration of platelets
Contract smooth muscle (PDG2,
PGF2a, TxA, PGG2, PGH2)
Relax smooth muscle (PGE2)
Elevate cyclic AMP
(PGE, PGD, PGI)
Elevate cyclic GMP
(PGF2a, PGG2)
Dose-dependent chemotactic
attraction or eosinophils or
neutrophils (HETE or HHT)
Hi classical
H2 thiourea
FPL-55712
Hydroxyzine
Cyproheptadine
lysergic acid
Unknown
ETYA (cyclo-
oxygenase
Nonsteroidal
Nonsteroidal
anti-inflammatory
Histaminase
(diamine oxidase)
or
Histamine
N-Methyl transferase
Arylsulfatases A and B
Monoamine oxidase
Phospholipases
Several specific
prostaglandin modifying
engymes
ECF-A
(preformed)
ECF-oligopeptides
(preformed)
NCF
(preformed)
Lipid chemotactic
factors
(newly generated)
Histamine
(preformed)
ValUAla-Gly-Ser-Glu,
MW 360-390
Peptides,
MW 1300-2500
Neutral protein,
MW > 750,000
? HHT
? HETE
? other lipids
/3-Imidazolyl-
ethylamine,
MW = 111
Chemotactic Activity
Chemotactic attraction and
deactivation of eosinophils
and neutrophils
Chemotactic attraction and
deactivation of eosinophils
and neutrophils
Chemotactic attraction of
deactivation of neutrophils
Chemotactic attraction of
neutrophils and eosinophils
Chemokinesis of neutrophils
Deactivation of neutrophils
Hi chemotactic and chemo-
kinetic activation of eosinophils
H2 chemotactic and chemo-
kinetic inhibition of neutrophils
and eosinophils
Gly-Ser-Glu
Val-Gly-Ser
Ala-Gly-Ser
Unknown
Unknown
Unknown
Hi classical
H2 thiourea
Amino-peptidase
Carboxy-peptidase A
Unknown
Unknown
Unknown
Histaminase
(diamine oxidase)
or
Histaminase
N-methyltransferase
Structural Components
Anticoagulation
Antithrombin III interaction
Inhibition of complement
activation
Environmental Health Perspectives
Heparin
(preformed)
Proteoglycan
MW - 60,000
Protamine Heparinase
156Table 1 (Cont'd).
Structural
Mediator characteristics Function Inhibition Inactivation
Chondroitin Proteoglycan Platelet factor IV interaction Unknown Chrondroitinase AC
4 and 6 sulfate
(preformed)
Dermatan sulfate Proteoglycan Unknown Unknown Chondroitinase ABC
(performed)
Enzymes
Chymase Protein Proteolysis with chymo- Serotonin Unknown
(preformed) MW = 29,000 tryptic specificity Heparin
Chymotrypsin
inhibitors
Arylsulfatase Proteins, Hydrolysis of SRS-A and P04, S04 product, Unknown
(preformed) MW = 100,000 (A) various sulfate esters substrate
60,000 (B)
N,N-Acetyl-,8-D- Protein, Cleavage ofglucosamine residues Product Unknown
glucosaminidase MW = 158,000
(preformed)
Basophil (lung) Protein, Proteolysis with tryptic specificity Trypsin inhibitors Unknown
kallikrein of MW 400,000 Cleavage of kinin from kininogen
anaphylaxis Cleavage of Hageman factor
(preformed)
f3-Glucuronidase Protein, Cleavage of glucuronide Product Unknown
MW _ 300,000 conjugates
large and small airways smooth muscle, thereby in-
creasing airway resistance and decreasing com-
pliance (11). It also dilates small radicles ofthe pul-
monary vascular tree and increases the distance
between endothelial cells of the venules, thereby
increasing the potential for transudation of serum
and for extravasation of leukocytes.
The biologic activities ofhistamine are expressed
by its interaction with either of two specific classes
of receptors on target cells. Those receptors desig-
natedHi predominate inskinandsmoothmuscleand
are blocked by classic antihistamines, while H2 re-
ceptors are selectively blocked by a group of com-
pounds, including the thiourea derivatives, burami-
mide, metiamide, and cimetidine (12). Pulmonary
bronchoconstriction, vasodilation and increased
cGMP are Hi effects, while H2 effects include inhi-
bition of both human lymphocyte-mediated cyto-
toxicity and IgE-mediated histamine release due to
elevation in cAMP content. Histamine inhibits
chemotaxis through H2 receptors, presumably also
by stimulating adenylate cyclase and increasing
cAMP.
Slow-ReactingSubstance ofAnaphylaxis (SRS-A).
Although SRS-A remains structurallyundefined, itis
likely an unsaturated acidic sulfur-containing lipid of
300-500 daltons (13). It is active as a constrictor of
peripheral airways to a much greater extent than of
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central airways (14) and causes vasodilation. Human
lung tissue, dispersed pulmonary cells, and nasal
polyps generate SRS-A during IgE-dependent
immunologic reactions. Decreasing amounts of
SRS-A are generated by increasingly pure human
lung mastcell preparations suggesting that cell types
other than mast cells alone are involved in its gener-
ation (3).
Presently the only acceptable assay for SRS-A
employs the antihistamine-treated guinea pig ileum,
but it is not specific for this mediator. Therefore,
SRS-A must be further identified by its chromato-
graphic properties, its susceptibility to inactivation
by arylsulfatases, and its decreased assayability in
the presence of a semispecific blocker, FPL55712.
Products ofArachidonic Acid Oxidation. In the
human, products of arachidonic acid metabolism
constitute the vast majority of prostaglandins and
related compounds. Arachidonic acid mobilized
from cell membrane phospholipids by the action
of phospholipase A2 is then either converted to
prostaglandins and thromboxanes via a cyclo-
oxygenase-dependent pathway or converted by a
lipooxygenase to 12-L-hydroxy-5,8,10,14 eicosa-
tetraenoic acid (HETE) and related compounds
(Fig. 3). Several of these products have been de-
scribed in vitro subsequent to noncytolytic activa-
tion of lung tissue and rat mast cells. Specifically,
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PDG2, PGI2, and HETE have been generated by
isolated rat mast cells, whereas PGF2o, and PGE2 are
present after IgE-dependent activation of human
lung tissue (15, 16). Guinea pig central airway
smooth muscle is constricted by PGF2a, throm-
boxane A2, and both cyclic endoperocides PGG2. In
the anesthetized dog, PGF2O, and PGD2 both con-
strict central and peripheral airways. Additional
pulmonary effects of generated prostaglandins are
likely, as elevations in cAMP and cGMP may be
consequent to their actions (17). While prostaglan-
dins of the E and F series may be identified by
radioimmunoassay, other arachidonic acid products
must be isolated and measured-by thin layer chro-
matography or gas chromatography-mass spectro-
scopy.
Platelet Activating Factors (PAF). PAF(s) are
immunologically generated subsequent to IgE-de-
pendent processes in human lung. Although PAF(s)
are themselves neither bronchospastic nor vaso-
active, theyinduce plateletrelease ofserotonin. This
monoamine contracts several smooth muscle prepa-
rations, but it is without apparent bronchospastic
effect on the human. PAF(s) may also induce platelet
aggregation and lead to the reversible sequestration
of platelets in the lung. The best chemically de-
scribed PAF(s) are apparently phospholipids, sus-
ceptible to inactivation by phospholipases (18). PAF
from different sources are not identical, as shown by
the inability of rabbit PAF from two sources to de-
activate platelets tothe biologic effects ofeach other
and by the somewhat different phospholipase inacti-
vation profiles ofrabbit leukocyte and rat peritoneal
PAF(s).
Chemotactic Mediators
Eosinophil Chemotactic Factor of Anaphylaxis
(ECF-A). The first mast cell-associated chemotac-
tic factor described, ECF-A, was identified in the
anaphylactic supernatant of challenged guinea pig
lung fragments and subsequently in the analogous
human tissue and isolated mast cells. This factor is
preferentially chemotactic for eosinophils. It also
deactivates this cell type to further migration. A
small peptide of about 400 daltons, ECF-A has also
beenidentifiedpreformed inhumanlungand isolated
mast cells (3). This mediator from human lung has
been structurally characterized as two acidic tet-
rapeptides with the amino acid sequence Val/Ala-
Gly-Ser-Glu (19).
Internediate Molecular Weight Eosinophil Chem-
otactic Peptides. In addition to low molecular
weight ECF-A tetrapeptides, human lung contains
chemotactic factors ofMW 1200-2500 with specific-
ity for eosinophil polymorphonuclear leukocytes
(20). These factors are preformed, immunologically
releasable and capable of deactivating eosinophils
(21).
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Factors (HMW-NCF). HMW-NCF has been de-
scribed in rat mast cells, human lung fragments, and
the serum of patients with cold urticaria (22) or
asthma (23) following challenge with ice water or
antigen inhalation, respectively. HMW-NCF has
been characterized as a 750,000-dalton neutral pro-
tein which attracts and deactivates neutrophils in
vitro. HMW-NCF appears to be a sensitive marker
for mast cell activation as it is present in serum
following challenge ofallergic asthmatics with doses
of antigen insufficient to induce bronchospasm.
Histamine. In addition to its smooth muscle di-
rected actions histamine is active in modulating the
migration of inflammatory leukocytes. Thus via an
Hi mechanism histamine enhances random and di-
rected migration of eosinophils and neutrophils and
is a weak chemotactic factor for human eosinophils.
By its H2 actions histamine inhibits both random and
directed migration of neutrophilic and eosinophilic
polymorphonuclear leukocytes (24).
Lipid Chemotactic Factors. The lipooxygenase
product ofarachidonic acid, HETE, has an ECF-A-
like spectrum ofactivity. Unlike ECF-A, however, it
increases eosinophil random migration and is a less
potent chemotactic deactivator than ECF-A (25).
Equivalent effects on neutrophils have also been
described for the cyclooxygenase product 12-L-
hydroxy-5,8,10-heptadecatrienoic acid (HHT) (25).
A possibly related factor is a nonpolar lipid with
chemotactic activity mainly for neutrophils which
has been described in anaphylactic diffusates of rat
mast cell-rich peritoneal cell preparations.
Structural Proteoglycans
The sulfated, metachromatic, mucopolysac-
charide heparin has been identified in human lung
and localized to the mast cells isolated from human
lung tissue (26). Human lung heparin is a proteogly-
can of approximately molecular weight 60,000 com-
prising a protein core to which are attached, by
xylosyl-seryl linkages, glycosaminoglycan side
chains of average molecular weight 20,000. Human
also heparin interacts with humanantithrombin III to
accelerate anticoagulation. Heparin from other
sources has been shown to inhibit generation of the
convertase enzyme (C3bBb) responsible for amplifi-
cation of cleavage of the third component of com-
plement (C3) (27), to inhibit binding of the Clq frag-
ment of complement to immune complexes (29), to
inhibit action of the activated first component of
complement (Cls) upon its substrates, thefourth(C4)
and second (C2) components (29), and to prevent
binding of C2 to C4b (30). In addition, heparin has
been shown to bind to platelet factor IV and to liber-
ate lipoprotein lipase.
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Granule-Associated Enzymes
Chymase. Chymase has been isolated from the
mast cell of the rat and has been identified histo-
chemically in the human mast cell (31). This enzyme
is minimally active as a protease while stored in the
granule, probably dueto maskingoftheactive siteby
heparin, but once freed its specific activity is com-
parable to that of pancreatic a-chymotrypsin.
Chymotrypsin inhibitors have been shown to inhibit
some inflammatory consequences ofIgE-dependent
activation in rabbit skin adding relevance tothe mast
cell location of this activity (32).
LungKallikrein ofAnaphylaxis. A preformed en-
zyme of400,000 molecular weight, termed lung kal-
likrein, is released subsequent to antigen challenge
of IgE-sensitized human lung fragments (33). This
activitycancleave kininogen to yield bradykininand
can activate Hageman factor. The released kinins
may contract bronchial smooth muscle and increase
vascular permeability. Kinins have also been noted
to induce bronchospasm when inhaled by asthmatic
humans and have been detected in the serum of a
single patient sustaining an acute asthma attack. Ac-
tivation of Hageman factor with the induction ofthe
clotting and fibrinolytic cascades could also be rea-
sonably expected to ensue upon release oflung kal-
likrein.
Arylsulfatase. Arylsulfatase has been identified in
human lung mast cells (3). Arylsulfatase A and B
enzymes can inactivate SRS-A and furthermore,
arylsulfatase A is immunologically released with the
mast cell granule in the rat (34).
Other Enzymes.,f-Glucuronidase and N-acetyl-
,8-D-glucosaminidase (hexosaminidase) have been
identified in human lung and in rat mast cells and
both are released upon immunologic activationofthe
rat mast cell (35). These enzymes in concert with
arylsulfatase, when obtained from sources other
than mast cells, have been demonstrated to degrade
ground substance mucopolysaccharides.
Mediator Interactions
Although the mediators of immediate type hyper-
sensitivity have been identified and assessed for
their effects as isolated factors some understanding
of their interactions is available. Thus the spas-
mogenic effects of histamine and SRS-A are syner-
gistic and in addition the presence ofeither directly
induces prostaglandin generation. The interactions
ofECF-A, histamine, and ECF-oligopeptides are not
fully delineated butit is known that histamine inhigh
concentrations inhibits and in low concentrations
enhances ECF-A-induced eosinophil chemotaxis. In
addition, the N and C terminal tripeptides ofECF-A
159are reversible and irreversible inhibitors of eosino-
philchemotaxis, respectively (37). Inaddition, PGEi
enhances and PGF2,,a inhibits neutrophil chemotaxis
probably by their actions upon cyclic nucleotide
concentrations. However, given the number and
complexity ofmast cell-dependent mediators other,
potentially critical, biologic interactions await eluci-
dation.
Determinants of Activity of
Mast Cell Mediators
Following activation of mast cells by IgE-depen-
dent or other mechanisms, the panoply ofmediators
generated and released and the myriad of their po-
tential interactions provides the substrate for induc-
tion ofinflammatory events. Theputativeroleforthe
mastcell and its mediators inboththehomeostatic as
well as pathophysiologic induction of inflammation
inthe lung is strengthened by the locationofthe mast
cell attherespiratory surface. Thusthe interaction of
surface and intraluminal mast cells with antigen or
noxious agents could, by the action of locally re-
leased permeability factors, lead to alterations ofthe
respiratory epithelial barrier thereby permitting ac-
cess to the large number of deeper situated mast
cells. Of more direct relevance has been the in vivo
demonstration that solely mast cell-dependent
events can indeed cause both immediate and more
persistent inflammatory processes. The biphasic re-
sponse ofairways toinhaled antigen maybecompar-
able to the biphasic cutaneous response to IgE-
dependent mast cell activation (38, 39). In the
cutaneous model awheal-and-flare response reflects
Lipid chemotctic and -
chemokinetic factors
altered vascular permeability at that site, whereas
later inflammatory events are accompanied by an
intense cellular infiltration (39). Immunochemical
studies have not revealed the participation of im-
mune complexes or complement during this later
inflammatory phase (39). Elicitation of both phases
by purely IgE-dependent mechanisms indicates that
mast cell activation can contribute to subacute and
chronic as well as to acute pathobiologic processes.
This fact is central to according the mast cell an
important role in asthma, since this disease is char-
acterized by acute exacerbations superimposed on
chronic hyperirritability of the airway. Whether
continued alteration in the threshold of airway re-
sponse is due to mast cell mediators directly or to
cellular infiltration is not established, but mast cell-
derived mediators could be critical by either route
alone or in combination.
The mechanism by which mast cell mediators
might provoke such biphasic inflammatory re-
sponses isdepicted in Figure 4. The mastcell depen-
dent generation of bronchospastic and vasoactive
mediators establishes a local vasodilatory or
humoral phase of inflammation while the release of
chemotactic mediators provokes a cellular phase of
inflammation. The humoral phase, apparent within
minutes, would lead to egress from the circulation of
immunoglobulin and complement as well as fibrino-
lytic, procoagulant and kinin-generating proteins.
This response could be expected to be rapidly bene-
ficial to the host by aiding removal of invading
microorganisms by localizing and removing noxious
agents, and by facilitating leukocyte migration
through venular disconnections. On the other hand,
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FIGURE 4. Schematic representation of mast cell dependent humoral and cellular inflammatory events.
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disease as acute exacerbations of bronchospasm,
alterations in tracheobronchial mucus flow or con-
sistency, or as upper airway obstruction due to
edema. The generation and release of chemotactic
factors would, in a period of several hours, be ex-
pected to call to the local inflammatory focus both
eosinophilic and neutrophilic polymorphonuclear
leukocytes. These cells could prove beneficial not
only by their phagocytic function but also by their
ability to inactivate mediators (see below). Con-
versely, if accumulation of leukocytes were
uncontrolled the pathobiologic consequences oftis-
sue infiltration with leukocytes would ensue. Clini-
cally, such infiltration might be seen in the inflam-
matorybronchial epitheliumofasthmatic patients, in
vasculitis, or perhaps, via the action of leukocytic
lysosomal enzymes, in the destruction oflung tissue
and the induction of fibrosis. By their capacities to
deactivate leukocytes to further chemotactic activa-
tion, mast cell chemotactic mediators might also in-
hibit localization of leukocytes. In cold urticaria,
following mediator release by experimental chal-
lenge, circulating neutrophils are rendered unre-
sponsive to in vitro chemotactic stimulation. This
effect is time limited but persists beyond the period
in which measurable quantities of mediators are
noted (40). Such an inhibitory action ofchemotactic
ACTIVATION SECRETION OF GRANULES
I
RELEASE
OF PRIMARY
MEDIATORS
factors could prove beneficial by blunting exuberant
inflammation or if prolonged or ill-timed might be
harmful by preventing adequate host response to
local insult. The release of mast cell proteases and
lysosomal enzymes may themselves lead to altera-
tions in ground substances and to activation of such
protein inflammatory cascades as complement,
fibrinolysis and coagulation. These processes would
amplify inflammatory events and might prove bene-
ficial to the elimination of microorganisms or toxic
agents but might also, if unregulated, lead to tissue
destruction, chronic inflammation and fibrosis.
Regulation of Mast Cell Mediator
Release and Activity
The events which lead to the generation and re-
lease ofmast cell mediators and thereby to the elici-
tation of mast cell dependent inflammatory events
are subject to regulation at several critical points.
Thus, activation of the mast cell, the secretion of
granules, the release ofthe preformed mediators and
generation of unstored mediators, the effect of
mediators upon target cells and finally the persis-
tence in tissue ofthe mediators are all underbiologic
control (Fig. 5).
The extent and effect ofactivation ofthe mast cell
is controlled by regulation of access of the eliciting
TARGET CELL ACTION BIODEGRADATION
Histamine - - - -- -
Int MW ECF
Histaminase
PERTURBATIOWN-.- MAST - ECF-A
CELL AryIsUdfatase B--
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FURTHER UNCOVERING -
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~~~I At
Lipid chematactic SRS-A PAF
and chemokinetic A I
factors L__ ____-
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A AI'l 1. A'l 1-11
I. A.1.-
FIGURE 5. Schematic representation of endogenous regulation of mediator expression with particular
emphasis on the role of the eosinophil.
April 1980 161agent tothis cell, the amount ofspecific IgEantibody
bound to the mast cell surface and by the intensity of
the stimulus. The mast cell itself might alter local
permeability allowing increased antigen contact, or
by the H2 action ofhistamine may suppress lympho-
cyte recognition of antigen and thereby prevent im-
mune response to invaders. In addition the ratio of
specific mediator generated is dependent upon the
intensity ofthe activating stimulus as limited stimu-
lation ofthe mast cell leads to intracellular accumu-
lation of SRS-A without release of SRS-A or his-
tamine (41). Intracellular mast cell arylsulfatases
may also control mediator generation by degrading
SRS-A prior to its release.
Subsequent to activation of the mast cell the
secretion of granules is under control of cyclic
nucleotides as noted above. Of direct relevance is
the possibility that the mast cell itself, by the
mediator histamine via an H2 action and prostaglan-
dins E2, D2, and 12 may directly elevate cAMP and
thereby inhibit granule secretion. Conversely, the
Hi action ofhistamine to elevate cGMP and that of
PGF2,a to lower cAMP levels might augment media-
tor release.
Following secretion of the mast cell granule, the
release of preformed mediators and thus the full ex-
pression oftheir activity is dependent upon the inde-
pendent solubilities of each of the mediators. Thus
,3-glucuronidase, arylsulfatase A, histamine,
ECF-A, and ECF-oligopeptides are fully soluble in
physiologic buffers, hexosaminidase requires 0.5M
NaCI for full elution from the granule and chymase-
heparin comnplex requires l.OM NaCl for dissolution
(34, 42). The relevance of granule binding is em-
phasized by the marked increase in proteolytic ac-
tivity of the chymase following its elution from the
granule. Although the mechanism(s) in which the
mast cell granule is solubilized in vivo remain un-
known, it is clearly an important step in regulating
the activity of mast cell inflammatory mediators.
Regulation of the action of mast cell mediators
upon target cells may derive from alterations in
cyclic nucleotide concentrations, as noted above, or
by the interaction of several mediators, or their
metabolites with the same target cell. Thus, his-
tamine may be additive or inhibitory to ECF-A ac-
tion upon eosinophils depending upon the ratioofthe
two activities present. In addition, the constituent
tripeptides of ECF-A are inhibitory to induction to
eosinophil chemotaxis by ECF-A. As noted above,
mediators may also be synergistic on smooth muscle
as exemplified by SRS-A and histamine action.
The regulation of generation of unstored media-
tors has not been fully elucidated but data suggest
that the local microenvironment is critical to their
generation. For example, SRS-A generation is
maximal in mixed rather than in pure mast cell
populations (3), and SRS-A, PAF and lipid chemo-
tactic factors can all be generated from monunuclear
leukocyte populations. The ratios of critical target
cells thus may be crucial to the amount and type of
mediator generated.
Finally, the persistence of the effect of mediators
is also regulated. While this may reflect the limited
availability of key mediators, probable tachyphy-
laxis to some, and mediator clearance by excretion,
it is also affected by enzymatic inactivation ofthese
biologic activities. As many mast cell-derived
chemotactic mediators are eosinophilotactic, the
eosinophil contentofmediator-inactivatingenzymes
may provide a feedback control of mediator effects
(Fig. 5). Notably, the eosinophil contains hista-
minase, arylsulfatase B, and phospholipase D,which
inactivate histamine, SRS-A, and PAF, respec-
tively. SRS-A is inactivated not only by extracted
eosinophil arylsulfatase, but also by the enzyme-rich
resting granulocyte, presumably after cellular up-
take of the mediator. Some other cells also contain
mediator-inactivating enzymes. Neutrophils contain
histaminase, and at least one mononuclear cell
population is rich in histamine methyltransferase.
Interestingly, both mast cells and basophils contain
arylsulfatase.
Inactivation of arachidonic acid metabolites is
complicated, as some intermediate metabolic prod-
ucts are biologically active. Thus PGD2 and throm-
boxane A2 derived from the cyclic endoperoxides
are potent bronchoconstrictors. However, most
stable catabolic end products of arachidonic acid
metabolism, such as thromboxane B2 (from throm-
boxane A2) and PG-6-keto-Fla (from PGI2) have
little or no defined biologic activity.
Conclusion
The mast cell-derived preformed and newly gen-
erated mediators are released by IgE-dependent and
independent mechanisms, and are biologically avail-
able during inflammatory events. The relevance of
these mediators to allergic disease has been derived
from studies of the pathophysiologic alterations in-
duced by the individual mediators, identification of
the mediators in tissue or biologic fluids of patients
experiencing allergic reactions, and the known
pathophysiology of the various atopic diseases.
Mediators of immediate hypersensitivity not only
possess the ability to induce immediate tissue re-
sponses such as a wheal and flare, anaphylaxis, or
rapid-onset brief-duration alterations in pulmonary
function, but may also mediate a prolonged inflam-
matory response. The factthat IgEand mastcells are
relevant to prolonged inflammatory events has been
Environmental Health Perspectives 162documented by passive transferwith isolated IgE, of
delayed inflammatory responses in skin and by the
dependence upon IgE antibody for similar delayed
alterations in pulmonary mechanics following inha-
lation of antigen. In lung, these delayed responses
are prevented by pretreatment with disodium
cromoglycate, which supports the central role ofthe
mast cell. Histopathologic assessment of delayed
responses reveals an influx of neutrophils, eosino-
phils, basophils, lymphocytes, and mononuclear
leukocytes, the deposition of fibrin, and vascular
abnormalities which may progress tofrank vasculitis
(39). Although some ofthe mediators responsiblefor
the early and later phases of the IgE-mast cell re-
action can be surmised from the kinetics of their
in vitro effects, their absolute identification and par-
ticipation in disease requires further definition.
The postulated role of the mast cell and its
mediators in inflammation may provide insight not
only into the clinical evolution of some allergic dis-
orders such as progression of seasonal to perennial
asthma, but also into the local homeostatic regula-
tion ofthe lung environment and thereby the defense
of the lung. Although much remains to be clarified,
the rapidly expanding understanding of target cell
activation together with the identification of mast
cell derived mediators provides a framework for
definition of the complex processes that provide
pulmonary defenses.
Dr. Wasserman is a recipient ofan Allergic Diseases Academic
Award (AI-00254) from the National Institutes of Health.
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